Rita C. Peters

Drug companies must consider all factors impacting the cost of drugs, including high costs of early development stages.

Hospitals form not-for-profit drug company to combat drug shortages and high prices.

A different perspective on controlling fixed costs of biomanufacturing, based on know-how from other industries, provides a competitive edge, says the CEO of Samsung BioLogics.

Bio/pharma professionals manage expectations amid industry uncertainty.

Will business decisions and drug pricing policies help or hinder science and drug approval advances in 2018?

Brexit-related challenges cast shadows on prospects for the European bio/pharma market in 2018, but optimism may let some sun shine through.

Attracting and retaining qualified bio/pharma experts demands a mix of recognition, rewards, and opportunities.

Is pharma up to the task of developing knowledgeable, motivated employees?

Amid business and regulatory uncertainty, bio/pharma experts reveal opinions on salary, recognition, and training.

Industry experts were honored for business, scientific, and social contributions.

Reeling from financial and tropical storms, Puerto Rico needs stable industry for recovery.

Faced with divisive political and social issues, Congress must find a way to reach consensus.

Amid contentious debate about “fake news,” peer-review papers offer vital, objective insight.

Pharmaceutical Technology marks 40 years covering the bio/pharma industry.

The more pharma science and technology change, the more business and policy concerns stay the same.

New study will reveal bio/pharma practices and performance on quality issues.

Philadelphia plays host to CPhI North America on May 16-18, 2017.

Drug type, potential sales, and ownership factor in the race to get drugs to market.

Reducing regulatory roadblocks requires more than the stroke of a pen.

Translating campaign promises to predictions for bio/pharma is difficult, but optimism prevails.

Healthcare policies, R&D investments, and drug approvals will test bio/pharma.

Estimates that global medicine spending will reach nearly $1.5 trillion by 2021 and the types of therapies and use of innovator versus generic drugs, will vary by region.

As Europe’s bio/pharma market learns that breaking up is hard to do, it also must address productivity, regulatory, and drug pricing challenges.

Rookie API developers beat pharma at its own game.

Survey reveals optimism, discontent, and a desire for better career opportunities.

Europe-based bio/pharma employees are unified on satisfaction with employment conditions-and dissatisfaction with salaries.

CPhI Pharma Award winners were recognized for sweating the details for the bigger picture.

PharmTech's Editorial Director, Rita Peters, addresses the CPhI Pharma Awards' finalists at this year's CPhI Awards Gala.

The editors seek drug development experts to contribute technical articles for 2017.

Steep price increases for a popular drug have created patient and Congressional backlash.